Table 1.
Intergroup rhabdomyosarcoma study pretreatment staging and clinical grouping classification
| Stage | Sites | T1 | Size2 | N3 | M4 |
| 1 | Orbit, head and neck (excluding parameningeal), genitourinary tract (non-bladder, non-prostate), biliary tract | T1 or T2 | a or b | N0 or N1 or Nx | M0 |
| 2 | Bladder.Prostate, extremity, parameningeal, others (trunk, retroperitoneum, etc.) | T1 or T2 | a | N0 or Nx | M0 |
| 3 | Bladder.Prostate, extremity, parameningeal, others (trunk, retroperitoneum, etc.) | T1 or T2 | a | N1 | M0 |
| b | N0 or N1 or Nx | M0 | |||
| 4 | Any sites | T1 or T2 | a or b | N0 or N1 | M1 |
| Clinical group | Description | ||||
| I | Localized disease, completely resected | ||||
| II | Grossly resected tumor with evidence of regional spread | ||||
| IIA: Grossly resected tumor with microscopic residual disease | |||||
| IIB: Involved regional nodes completely resected with no microscopic residual disease | |||||
| IIC: Involved regional nodes grossly resected with evidence of microscopic residual disease | |||||
| III | Incomplete resection with gross residual disease after biopsy or after gross or major resection of the primary tumor | ||||
| IV | Distant metastatic disease present at diagnosis | ||||
1
T: Tumor; T1: Confined to the anatomic origin; T2: Extension and/or fixation to surrounding tissue;
2
Size, a: ≤ 5 cm; b: > 5 cm;
3
N: Regional nodes; N0: Regional nodes not clinically involved; Nx: Clinical status of regional nodes unknown; N1: Regional nodes clinically involved;
4
M: Metastasis; M0: No distant metastasis; M1: Distant metastasis present (includes positive cytology in pleural, peritoneal or cerebrospinal fluid).